About AbCellera Biologics Inc.
https://www.abcellera.comAbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
CEO
Carl L.G. Hansen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 30
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:27.53M
Value:$118.08M
CAPITAL WORLD INVESTORS
Shares:13.36M
Value:$57.32M
BAILLIE GIFFORD & CO
Shares:10.42M
Value:$44.71M
Summary
Showing Top 3 of 167
About AbCellera Biologics Inc.
https://www.abcellera.comAbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.96M ▼ | $85.23M ▲ | $-57.12M ▼ | -637.84% ▼ | $-0.19 ▼ | $-40.22M ▼ |
| Q2-2025 | $17.08M ▲ | $59.61M ▼ | $-34.73M ▲ | -203.27% ▲ | $-0.12 ▲ | $-38.83M ▲ |
| Q1-2025 | $4.24M ▼ | $66.89M ▼ | $-45.62M ▼ | -1.08K% ▼ | $-0.15 ▼ | $-51.9M ▲ |
| Q4-2024 | $5.05M ▼ | $77.81M ▲ | $-34.21M ▲ | -677.43% ▲ | $-0.12 ▲ | $-55.31M ▼ |
| Q3-2024 | $6.51M | $61.88M | $-51.11M | -785.42% | $-0.17 | $-51.88M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $520.67M ▼ | $1.36B ▼ | $391.95M ▼ | $964.04M ▼ |
| Q2-2025 | $553.08M ▼ | $1.4B ▲ | $394.99M ▲ | $1.01B ▼ |
| Q1-2025 | $605.27M ▼ | $1.34B ▼ | $321.23M ▲ | $1.02B ▼ |
| Q4-2024 | $625.61M ▼ | $1.36B ▼ | $304.47M ▼ | $1.06B ▼ |
| Q3-2024 | $643.14M | $1.39B | $314.73M | $1.08B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-57.12M ▼ | $-52.59M ▼ | $36.49M ▲ | $7.37M ▲ | $-9.28M ▲ | $-61.52M ▼ |
| Q2-2025 | $-34.73M ▲ | $-32.4M ▼ | $-31.81M ▼ | $-3.38M ▼ | $-66.83M ▼ | $-45.77M ▼ |
| Q1-2025 | $-45.62M ▼ | $-11.55M ▼ | $7.93M ▼ | $5.97M ▲ | $2.94M ▼ | $-22.19M ▲ |
| Q4-2024 | $-34.21M ▲ | $-8M ▲ | $35.7M ▲ | $4.14M ▲ | $29.68M ▲ | $-23.63M ▲ |
| Q3-2024 | $-51.11M | $-29M | $3.94M | $3.15M | $-21.67M | $-47.58M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $10.00M ▲ | $0 ▼ |
 Research Fees | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
CEO
Carl L.G. Hansen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 30
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:27.53M
Value:$118.08M
CAPITAL WORLD INVESTORS
Shares:13.36M
Value:$57.32M
BAILLIE GIFFORD & CO
Shares:10.42M
Value:$44.71M
Summary
Showing Top 3 of 167